TGFB1 and renal fibrosis: Despite the existing clinical treatments for renal fibrosis, such as angiotensin inhibitors and transforming growth factor-beta (TGF-β) inhibitors [13], they exhibit limitations like dose-dependent effects, extrarenal impacts, and aldosterone escape, resulting in suboptimal outcomes [14].